SAGE / Sage Therapeutics to lay off 40% of staff after FDA rejects Zurzuvae  for 'major depressive disorder'

Sage Therapeutics, Inc. received FDA approval along with Biogen for its drug ZURZUVAE for the treatment of postpartum depression, with a planned launc more_horizontal

Shares of Sage Therapeutics Inc jumped 5% in premarket trading following the announcement that the US Food and Drug Administration (FDA) has granted more_horizontal

The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to cond more_horizontal

SAGE Therapeutics (NASDAQ:SAGE) has announced a major reorganization, including laying off about 40% of its workforce, after the US Food & Drug Admini more_horizontal

Sage Therapeutics said on Thursday it would cut its workforce by about 40%, weeks after the U.S. health regulator declined to approve its drug to trea more_horizontal

The Food and Drug Administration only granted partial approval to zuranolone this month. Sage is an unprofitable business, so it's a big blow that ens more_horizontal

The FDA approved Zurzuvae for postpartum depression but not for major depressive disorder. Sage saw revenues and net losses climb in the second quarte more_horizontal

Sage Therapeutic shares fell to an all-time low after the FDA rejected use of its treatment for major depressive disorder. more_horizontal